FDA hits Chinese OTC drugmaker with warning letter over data, testing issues

fda
The FDA has issued a warning letter to Chinese OTC drugmaker Zhejiang Ludao Technology over data integrity and product testing issues.

The FDA issued a warning letter to Chinese OTC drugmaker Zhejiang Ludao Technology, citing data integrity and product testing issues.

In the warning letter, the regulatory agency said the company lacked basic laboratory controls to prevent changes to paper and electronic records. The FDA also noted that the company admitted during an inspection in August to falsifying certificates of analysis for four batches of OTC products before the products were manufactured.

Additionally, inspectors found computer files in the recycling bin for the company's standalone high-performance liquid chromatography system. In its warning, the FDA said the system did not have audit trail capabilities and the company was unable to explain why the files were deleted.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Before the inspection last summer, the agency detained and tested samples from a batch of an OTC spray made by Zhejiang Ludao that had nearly twice the amount of active ingredient specified on the label. According to the FDA, the company has agreed to reformulate the spray and update its test methods to conform to the corresponding USP monograph.

Zhejiang Ludao was placed on an import alert in late December.

In November, the agency slapped a warning letter on another Chinese OTC drug manufacturer that shipped multiple lots of an OTC product to the U.S. containing the wrong API because the company messed up a translation. That warning went to Guangdong Zhanjiang Jimin Pharmaceutical and cited a number of issues, including the discovery that it was using the wrong API for an anti-itch product that was labeled as containing hydrocortisone.

Read more on

Suggested Articles

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

Find out how PDA can help you succeed with custom solutions and training for your employees – at your facility, our facility, or virtually.

United Airlines last week delivered the first doses of Pfizer's vaccine from Belgium to the U.S. as the drugmaker preps for a potential December nod.